Epilepsy Archives - Purablis-Medicinal Tinctures with CBD, THCA and THC

Epilepsy Marijuana Studies and

Epilepsy Cannabis Research

09/28/2018

Author(s): Marta Rubio, Sara Valdeolivas, Fabiana Piscitelli, Roberta Verde, Valentina Satta, Eva Barroso, Marisol Montolio, Luis Miguel Aras, Vincenzo Di Marzo, Onintza Sagredo & Javier Fernandez-Ruiz.

This study demonstrates that CBD or cannabidiol helps reduce seizures of childhood epilepsy, and dravets syndrome. View study

09/28/2018

Author(s): Nicholas A. Jones, Sarah E. Glyn, Satoshi Akiyama, Thomas D.M. Hill, Andrew J. Hill, Samantha E. Weston, Matthew D.A. Burnett, Yuki Yamasaki , Gary J. Stephens, Benjamin J. Whalley, Claire M. Williams.

In this study, cannabidiol is evidenced as a strong candidate to treat human epilepsies, since it reduces the severity of seizures. View study

09/28/2018

Author(s): Mahshid Hosseinzadeh1 & Sara Nikseresht1 & Fariba Khodagholi 1,2 & Nima Naderi 1,3 & Nader Maghsoudi 1,2.

In the chronic phase of epilepsy, post-treatment with cannabidiol could be considered as a protection mechanism of the temporal lobe, which improves the induction of the cellular autophagy pathway and antioxidant defense. View study

09/28/2018

Author(s): Naoki Amada, Yuki Yamasaki, Claire M. Williams and Benjamin J. Whalley.

The anticonvulsant effects of cannabinoid cannabidivarin (CBDV) at the molecular level have been evaluated, confirming the behavioral effects on chemically induced seizures, highlighting their quality for clinical development. View study

09/28/2018

Author(s): TDM Hill, M-G Cascio, B Romano, M Duncan, R G Pertwee,C M Williams, B J Whalley and A J Hill.

Botanical substances (BDS) derived from cannabis, rich in cannabidivarin (CBDV) and cannabidiol (CBD), showed anticonvulsant properties in three crisis models that were not mediated by the CB1 cannabinoid receptor. These findings support the clinical development of CBDV BDS for the treatment of epilepsy. View study

09/28/2018

Author(s): Robert E. Blair, Laxmikant S. Deshpande, Sompong Sombati, Katherine W. Falenski, Billy R. Martin, and Robert J. DeLorenzo.

Cannabinoids have anticonvulsant properties, but their effects have not been evaluated in hippocampal neuronal culture models of acquired epilepsy (AD) and status epilepticus (SE). The results of this study represent powerful tools to investigate the molecular mechanisms that mediate the effects of cannabinoids on neuronal excitability. View study

09/28/2018

Author(s): Melisa J. Wallace, Jenny L. Wiley, Billy R. Martin, Robert J. DeLorenzo.

It has been shown that cannabinoids are anticonvulsants in the maximum electroshock. This study establishes a role for the CB1 receptor in modulating convulsive activity in an animal model. View study

09/28/2018

Author(s): Nicholas A. Jones, Andrew J. Hill, Imogen Smith, Sarah A. Bevan, Claire M. Williams, Benjamin J. Whalley, and Gary J. Stephens.

It is demonstrated that phytocannabinoids have important therapeutic properties, and specifically cannabidiol or CBD has anticonvulsant properties in animal models which highlights its potential as a new antiepileptic drug. View study

09/28/2018

Author(s): Elizabeth A Thiele, Eric D Marsh, Jacqueline A French, Maria Mazurkiewicz-Beldzinska, Selim R Benbadis, Charuta Joshi, Paul D Lyons, Adam Taylor, Claire Roberts, Kenneth Sommerville, on behalf of the GWPCARE Study Group.

The Lennox-Gastaut syndrome is a severe form of epileptic encephalopathy resistant to conventional treatments. It has been shown that cannabidiol is effective for the treatment of patients with gout attacks associated with Lennox-Gastaut syndrome and is generally well tolerated. View study

09/28/2018

Author(s): Naoki Amada, Yuki Yamasaki, Claire M. Williams and Benjamin J. Whalley.

The anticonvulsant effects of cannabinoid cannabidivarin (CBDV) at the molecular level have been evaluated, confirming the behavioral effects on chemically induced seizures, highlighting their quality for clinical development. View study

09/28/2018

Author(s): AJ Hill, MS Mercier, TDM Hill, SE Glyn, NA Jones,Y Yamasaki, T Futamura, M Duncan, CG Stott, GJ Stephens,CM Williams and BJ Whalley.

The anticonvulsant profile of cannabidivarin CBDV is investigated for the first time in invitro and in vivo models, demonstrating that it is an effective anticonvulsant without significantly affecting normal motor function. View study

09/28/2018

Author(s): TDM Hill, M-G Cascio, B Romano, M Duncan, R G Pertwee,C M Williams, B J Whalley and A J Hill.

Botanical substances (BDS) derived from cannabis, rich in cannabidivarin (CBDV) and cannabidiol (CBD), showed anticonvulsant properties in three crisis models that were not mediated by the CB1 cannabinoid receptor. These findings support the clinical development of CBDV BDS for the treatment of epilepsy. View study

09/28/2018

Author(s): Francis M. Filloux.

Trials and controlled studies on the effects of cannabidiol in children with epilepsy have shown high quality medical evidence regarding its therapeutic benefits. View study

09/28/2018

Author(s): Daniel Friedman, M.D., and Orrin Devinsky, M.D.

Studies in humans suggest that cannabidiol (CBD) and Δ9-THC may have beneficial properties for the treatment of epilepsy. However, these studies are quite limited and therefore it is not possible to draw conclusions about them. If randomized clinical trials show that specific cannabinoids are safe and effective, those preparations should be approved and made available. View study

09/28/2018

Author(s): Author: Benjamin J Whalley. Editors: Lyle Craker, Mahmoud A ElSohly, Aviva Romm, Ethan Russo, Roy Upton.

Although cannabis and its components possess potentially beneficial properties for the treatment of epilepsy, the psychotropic effects of Δ9-THC limit or prohibit its generalized therapeutic use. If it is possible to confirm the anticonvulsant effects for crude non-psychoactive galenic preparations, it could offer an alternative to psychoactive cannabis preparations and standard medications. View study

09/28/2018

Author(s): Michal Tzadoka, Shimrit Uliel-Sibonib, Ilan Linderc, Uri Kramerb, Orna Epsteind,Shay Menascub, Andrea Nissenkorna, Omer Bar Yosefa, Eli Hymand, Dorit Granote, Michael Dorf, Tali Lerman-Sagiec, Bruria Ben-Zeev.

A study was conducted with the objective of confirming the positive effects of medicinal cannabis enriched with cannabidiol (CBD) in children with epilepsy. As a result of this study, 89% of children reported a reduction in the frequency of seizures. However, 7% of patients reported aggravation of seizures that led to abstinence from CBD. In general, these results are very promising. It is necessary to perform more prospective and well designed clinical trials

09/28/2018

Author(s): Jormar M. Cunhu, E.A. Carlini, Aparecido E. Pereira, Oswaldo L. Ramos, Camilo Pimentel, Rubens Gagliardi. W.L. Sanvito, N. Lander and R. Mechoulam.

According to the results of this study, cannabidiol (CBD) has the potential to become an antiepileptic drug, as well as having a possible potentiating effect on other antiepileptic drugs. It was found that CBD has a beneficial effect in patients with secondary generalized epilepsy with temporal focus. View study

09/28/2018

Author(s): Orrin Devinsky, Joseph Sullivan, Daniel Friedman, Elizabeth Thiele, Eric Marsh, Linda Laux, Ian Miller, Robert Flamini, Angus Wilfong, Francis Filloux, Matthew Wong, Nicole Tilton, Patricia Bruno, Rebecca Kamens, Jane Maclean, Judith Bluvstein, Srishti Nangia, Anup Patel, Maria Roberta Cilio.

This study has obtained promising results for Epidiolex (cannabidiol) as a drug for treatment in children with a variety of epilepsy syndromes. It was found that children and young adults with Dravet’s syndrome had the greatest reduction in seizures. More randomized controlled trials are being conducted to support these results. View study

09/28/2018

Author(s): Melisa J. Wallace, Billy R. Martin, Robert J. DeLorenzo.

The cannabinoids Anandamida and its analog, O-1812, have been shown to be effective anticonvulsants in animal models, further evidencing that the cannabinoid receptor CB1 is one of the main mediators of the modulation of seizures. View study

09/28/2018

Author(s): Rüdiger Lorenz.

A study about the therapeutic application of THC in children and adolescents with neurodegenerative diseases, epilepsy and other chronic conditions, showed that THC reduced spasticity, provoked improved dystonia, and had anticonvulsive actions. View study

09/28/2018

Author(s): Kamil Detyniecki & Lawrence Hirsch.

In recent years the interest for the use of cannabinoids for the treatment of epilepsy has grown. This review answers the most significant questions that doctors have about the use of cannabis in the treatment of epilepsy. View study

09/28/2018

Author(s): Maria R. Karlocai, Kinga Toth, Masahiko Watanabe, Catherine Ledent, Gabor Juhasz, Tamas F. Freund, Zsofia Magloczky.

The endogenous cannabinoid system plays a fundamental role in retrograde synaptic communication and controls the propagation of activity in an epileptic network. Changes in the pattern of CB1 cannabinoid receptor expression are associated with the severity of the hippocampal lesion, caused by acute seizures that eventually lead to sclerosis. View study

09/28/2018

Author(s): Brenda E. Porter and Catherine Jacobson.

This study is based on a survey that shows that parents are using cannabis enriched with CBD for the treatment of severe epilepsy in children, and the beneficial effects of this treatment. View study

09/28/2018

Author(s): Maria Roberta Cilio, Elizabeth A. Thiele, and Orrin Devinsky.

Pure CBD (the main non-psychotropic compound of Cannabis sativa), due to its anticonvulsant properties, seems to be an ideal candidate as therapy for epilepsy resistant to conventional treatment. View study